{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:32Z","timestamp":1789133132885,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Invasive mold diseases (IMD) is associated with high mortality and a substantial economic burden. For high-risk patients, fever drive or diagnostic drive therapy is usually initiated prior to the differential diagnosis of the pathogen. This study evaluated the cost-effectiveness of isavuconazole, posaconazole, vs. voriconazole in the treatment of IMD from the perspective of the Chinese healthcare system, informing healthcare decision-making and resource allocation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision analytic model was constructed using TreeAge Pro 2011 software to evaluate the cost-effectiveness of the entire disease course. We assumed that the prevalence of mucormycosis in the patients entering the model was 7.8%. Efficacy, cost, adverse events, and other data included in the model were mainly derived from clinical studies, published literature, and publicly available databases. The primary outcomes of the model output were total cost, quality-adjusted life years (QALYs), life years (Lys), and incremental cost-effectiveness ratio (ICER). The willing-to-pay (WTP) threshold was defined as one to three times China's GDP per capita in 2022. One-way sensitivity analysis and probability sensitivity analysis were used to determine the robustness of the model. At the same time, the cost-effectiveness of three triazole antifungal agents under a broader range of mucormycosis prevalence, when voriconazole was covered by medical insurance reimbursement, and after the price reduction of posaconazole was discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with voriconazole, isavuconazole provided an additional 0.38 Lys (9.29 vs. 8.91 LYs) and 0.31 QALYs (7.62 vs. 7.31 QALYs); ICER was $15,702.46\/QALY, well-below the WTP threshold ($38,223\/QALY). However, posaconazole did not provide a significant economic advantage over voriconazole (9.40 vs. 9.36 Lys; 7.71 vs. 7.68 QALYs; ICER $64,466.57\/QALY). One-way sensitivity analysis found that ICER was highly sensitive to the mortality of patients with invasive <jats:italic>aspergillus<\/jats:italic> infection. In the probabilistic sensitivity analysis, when the WTP threshold was $38,223\/QALY, the probability of isavuconazole being cost-effective was 72.9%. The scenario analysis results indicated that posaconazole would become cost-effective when the price was reduced by 15% or the prevalence of mucormycosis was 14%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Isavuconazole represents a cost-effective initial option for treating IMD in high-risk hematological patients prior to the differential diagnosis of pathogens. It will also be economical when a 15% reduction in posaconazole cost is achieved.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1292162","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:48:06Z","timestamp":1702975686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Guangxin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Ther Clin Risk Manag."},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.riam.2021.03.003","article-title":"Invasive fungal infection over the last 30 years","volume":"38","author":"Silva","year":"2021","journal-title":"Rev Iberoam Micol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3760\/cma.j.issn.0366-6999.20121945","article-title":"Epidemiology of opportunistic invasive fungal infections in China: review of literature","volume":"126","author":"Liao","year":"2013","journal-title":"Chin Med J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11684-017-0601-0","article-title":"Epidemiology of fungal infections in China","volume":"12","author":"Chen","year":"2018","journal-title":"Front Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1469-0691.2011.03503.x","article-title":"Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China","volume":"18","author":"Xu","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jcpt.13643","article-title":"Treatment and economic burden of mucormycosis in China: Case report review and burden estimation","volume":"47","author":"Jian","year":"2022","journal-title":"J Clin Pharm Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica."},{"key":"B8","first-page":"195","article-title":"Opportunistic invasive fungal infections: diagnosis & clinical management","volume":"139","author":"Badiee","year":"2014","journal-title":"Indian J Med Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1399-3062.2007.00264.x","article-title":"Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey","volume":"10","author":"Sink\u00f3","year":"2008","journal-title":"Transpl Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw444","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13696998.2019.1638789","article-title":"The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom","volume":"23","author":"Floros","year":"2020","journal-title":"J Med Econ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden","volume":"19","author":"Floros","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/myc.13189","article-title":"The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain","volume":"64","author":"Azanza","year":"2021","journal-title":"Mycoses."},{"key":"B19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/sj.leu.2405065","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","author":"Raad","year":"2008","journal-title":"Leukemia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B\u2013based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7882","DOI":"10.1128\/AAC.02107-15","article-title":"Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified mucorales species","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"835037","DOI":"10.3389\/fphar.2022.835037","article-title":"External evaluation of population pharmacokinetic models of busulfan in Chinese adult hematopoietic stem cell transplantation recipients","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00228-022-03359-2","article-title":"External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy","volume":"78","author":"Huang","year":"2022","journal-title":"Eur J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E396","DOI":"10.1111\/j.1469-0691.2012.03908.x","article-title":"Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)","volume":"18","author":"Xhaard","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3969\/j.issn.1009-5519.2020.17.018","article-title":"Comparison of short-term efficacy and cost-effectiveness ratio of artificial liver in treatment of acute (subacute)-on-chronic liver failure","volume":"36","author":"Xie","year":"2020","journal-title":"J Modern Med Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ejh.12324","article-title":"Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study","volume":"93","author":"Leunis","year":"2014","journal-title":"Eur J Haematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1038\/bcj.2016.3","article-title":"Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life","volume":"6","author":"Bower","year":"2016","journal-title":"Blood Cancer J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach","volume":"7","author":"Bergamasco","year":"2021","journal-title":"J Fungi."},{"key":"B31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/myc.12428","article-title":"Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis","volume":"58","author":"Jeong","year":"2015","journal-title":"Mycoses."},{"key":"B33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000196477","article-title":"Pulmonary aspergillosis: early diagnosis improves survival","volume":"62","author":"von Eiff","year":"1995","journal-title":"Respiration."},{"key":"B34","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J Mycol Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e12751","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1292162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:48:13Z","timestamp":1702975693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1292162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2023.1292162"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1292162","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"article-number":"1292162"}}